Results 151 to 160 of about 84,026 (244)

A systematic qualitative review of ethical issues in open label placebo in published research. [PDF]

Sci Rep
Richard M, Bernstein M, Gaab J, Elger B.
europepmc   +1 more source

Effect of calcifediol supplementation as add-on therapy on the immune repertoire in recipients of the ChAdOx1 nCoV-19 vaccine: A prospective open-label, placebo-controlled, clinical trial. [PDF]

J Infect, 2023
Bhat S, Das L, Maheshwari D, Badal D, Sarkar R, Gupta M, Pandav SS, Padhi BK, Bhadada SK, Holick MF, Dutta P, Sachdeva N, Marwaha RK.   +12 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

The association between test anxiety, learning strategies, and open-label placebo effects on academic test performance: a secondary analysis of a randomized controlled trial. [PDF]

Front Psychol
Frisaldi E, Kleine-Borgmann J, Hartmann H, Benson S, Bingel U, Schmidt K.   +5 more
europepmc   +1 more source

How orthopedic surgeons view open label placebo pills: Ethical and effective, but opposed to personal use. [PDF]

J Psychosom Res, 2021
Bernstein MH, Rosenfield M, Fuchs N, Magill M, Blease CR, Beaudoin FL, Rich JD, Wartolowska K, Terek RM.   +8 more
europepmc   +1 more source

An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adults

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paroxetine is a selective serotonin reuptake inhibitor (SSRI), approved for treatment of major depressive disorder and anxiety disorders. Some SSRIs are known to prolong the QT interval; however, clinical evidence to establish a lack of association between paroxetine and corrected QT interval (QTc) prolongation is limited. Therefore, this
Sven C. van Dijkman, Mathieu Félices, Bhaskar Pandurangavittal, Sanman Ghorpade, Caroline Easterbrook, Marcin Zabielski, Oscar Della Pasqua   +6 more
wiley   +1 more source

Open label placebo for chronic low back pain: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Pain Manag
Flávio-Reis VHP, Pessoa-Gonçalves YM, Diaz CAV, Lamoglia ASA, Desidério CS, Oliveira CJF.   +5 more
europepmc   +1 more source

Low‐intervention clinical trials in Spain: Do they progress?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory ...
Claudia Erika Delgado‐Espinoza, Mayro J. Cortés Pestana, Kristopher Amaro, Rosa M. Antonijoan, Caridad Pontes   +4 more
wiley   +1 more source

Assessment of Safety, Tolerability, Pharmacokinetics, and Volume-Dependent Conductive Hearing Loss in Healthy Volunteers: First-in-Human, Open-Label, Placebo-Controlled Study of a Single Intratympanic Injection of AC102. [PDF]

Otol Neurotol
Lanting C, Robijn S, Nieratschker M, Galetzka C, Meis A, Rommelspacher H, Ahoud-Schoenmakers S, Lackner E, Zeitlinger M, Bauer M, Arnoldner C, Pennings R, Schlingensiepen R.   +12 more
europepmc   +1 more source

Lay perspectives of the open-label placebo rationale: a qualitative study of participants in an experimental trial. [PDF]

BMJ Open, 2021
Locher C, Buergler S, Frey Nascimento A, Kost L, Blease C, Gaab J.   +5 more
europepmc   +1 more source